February 24, 2024
You are here:  Home  >  Banking & Finance  >  Current Article

Atara treatment nears European approval


The biotechnology industry is a risky business, for the companies, their executives and their investors. Formulating a new medicine or treatment can take years and cost hundreds of millions of dollars, and, by the end, the federal agencies in charge of approving the product could decide the upside is not worth the risk. After seven…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.